Stock comparison
Genmab A/S
Innoviva
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
INVA
Innoviva
Market cap
$1.66B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | INVA | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 51C | GMAB |
| Benjamin Graham | 64C | 50C | GMAB |
| Philip Fisher | 48D | 44D | GMAB |
| Peter Lynch | 25F | 16F | GMAB |
| Joel Greenblatt | 76B | 32F | GMAB |
| Charlie Munger | 68C | 47D | GMAB |
| Terry Smith | 71C | 46D | GMAB |
Side-by-side metrics
| Metric | GMAB | INVA |
|---|---|---|
| Market cap | $16.5B | $1.66B |
| P/E (TTM) | 6.2x | 3.3x |
| EV/EBIT | 12.0x | 8.6x |
| ROIC (TTM) | 43.78% | 2.93% |
| Gross margin | 93.88% | 76.2% |
| Net margin | 18.23% | 118.91% |
| Revenue CAGR 5y | -18.45% | 2.06% |
| EPS CAGR 5y | -23.48% | 5.54% |
| Debt / Equity | 0.1x | 0.2x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- ROIC (TTM)43.78%vs 2.93%+93%
- Market cap$16.5Bvs $1.66B+90%
- Debt / Equity0.1xvs 0.2x+70%
- Gross margin93.88%vs 76.2%+19%
INVA leads on
- EPS CAGR 5y5.54%vs -23.48%+124%
- Revenue CAGR 5y2.06%vs -18.45%+111%
- Net margin118.91%vs 18.23%+85%
- P/E (TTM)3.3xvs 6.2x+46%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.